Skip to main content
Sartorius Stedim Biotech logo

Sartorius Stedim Biotech — Investor Relations & Filings

Ticker · DIM ISIN · FR0013154002 LEI · 52990006IVXY7GCSSR39 PA Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2026-04-23 Earnings Release
Country FR France
Listing PA DIM

About Sartorius Stedim Biotech

https://www.sartorius.com/en

Sartorius Stedim Biotech is a leading international provider of equipment and services for the biopharmaceutical industry. The company offers integrated solutions that support the entire lifecycle of drug development and manufacturing, from research and development to quality assurance and commercial production. Its comprehensive portfolio includes technologies for filtration, fluid management, fermentation, cell culture, and purification. Key products encompass bioreactors, single-use systems, process filtration equipment, cell culture media, and data analytics software. Sartorius Stedim Biotech enables its customers to develop and manufacture biotech medications, including cell and gene therapies, more efficiently and safely, helping to accelerate the translation of scientific discoveries into patient care.

Recent filings

Filing Released Lang Actions
Sartorius Stedim Biotech publie ses résultats non audités pour le premier trimestre de l’exercice 2026
Earnings Release Classification · 1% confidence The document is a press release dated 23 April 2026 announcing Sartorius Stedim Biotech’s first‐quarter 2026 financial results, providing key revenue and profit highlights, growth rates, and management commentary. It is an initial announcement of quarterly financial results, not a complete interim report, and fits the definition of an Earnings Release. Q1 2026
2026-04-23 French
Sartorius Stedim Biotech reports robust first-quarter results for fiscal 2026
Earnings Release Classification · 1% confidence The document is a press release announcing the company’s first-quarter fiscal 2026 financial results, including sales, EBITDA, net profit, guidance confirmation, and a conference call invitation. It highlights key quarterly figures rather than providing a full interim report with comprehensive notes. This matches the definition of an Earnings Release (ER). Q1 2026
2026-04-23 English
Sartorius Stedim Biotech SA: DECLARATION RELATIVE AU NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
Regulatory Filings Classification · 1% confidence The document is a formal declaration of the total number of shares and voting rights under French commercial code and AMF regulations, published periodically (monthly) rather than as part of a shareholder meeting or threshold crossing. It does not announce AGM materials, earnings, management changes, or threshold crossings, so it falls under a general regulatory announcement. Therefore, it is classified as a Regulatory Filing (RNS).
2026-04-02 French
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Regulatory Filings Classification · 1% confidence The document is a statutory declaration under French commercial code and AMF regulations detailing the total number of shares and voting rights as of a specific date. It does not announce a new share issue, dividend, or major shareholding threshold crossing, nor is it an earnings, management, or ESG report. It is a mandatory periodic regulatory filing. Therefore it best fits the fallback category Regulatory Filings (RNS).
2026-04-02 English
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Regulatory Filings Classification · 1% confidence The document is a brief regulatory news announcement under AMF rules disclosing the total number of shares and voting rights in the issued capital of Sartorius Stedim Biotech SA. It is not an AGM presentation, earnings release, change in management, nor a full financial report. It is a standard French regulatory filing of share capital and voting rights information. This fits best under the general “Regulatory Filings” category (RNS) as a fallback for miscellaneous regulatory disclosures.
2026-04-02 English
Resolutions of the Combined Annual Shareholders Meeting of Sartorius Stedim Biotech S.A.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release summarizing the resolutions passed at the Combined Annual Shareholders’ Meeting, including voting outcomes (discharge of directors, board composition changes, and dividend approval). This is exactly a declaration of voting results at an AGM, matching category DVA.
2026-03-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.